Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORTREL 0.5/35-28 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone and ethinyl estradiol are a combination hormonal contraceptive. Norethindrone suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and enhances the contraceptive effect by inhibiting gonadotropin secretion.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy,Oral contraceptive (off-label: treatment of acne, abnormal uterine bleeding, dysmenorrhea)
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
1 tablet orally once daily for 28 days (21 active tablets containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol, followed by 7 placebo tablets).
400 mg orally once daily with food.
Norethindrone: 7.2-9.2 hours; Ethinyl estradiol: 13-27 hours. Clinical context: Steady state reached in 5-7 days; half-life supports once-daily dosing.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Norethindrone: primarily hepatic via reduction and sulfation; CYP3A4 involved. Ethinyl estradiol: hepatic via CYP3A4; undergoes first-pass metabolism and enterohepatic recirculation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites; <5% unchanged.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Norethindrone: 61% bound to albumin, 36% to SHBG; Ethinyl estradiol: 97% bound to albumin, 2% free.
98% bound to albumin
Norethindrone: 3.6-4.3 L/kg; Ethinyl estradiol: 2.3-3.7 L/kg; indicates extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: Norethindrone ~64% (extensive first-pass metabolism); Ethinyl estradiol ~43-45% (due to first-pass and gut wall metabolism).
Oral: 85-90%; IM: 95-100%
No dose adjustment required for GFR ≥30 m L/min. Use is not recommended in patients with GFR <30 m L/min or on dialysis due to potential decrease in hormone clearance and increased risk of adverse effects.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in patients with Child-Pugh class B or C hepatic impairment. For Child-Pugh class A, use is not recommended due to potential reduced hormone metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use in pediatric patients before menarche. For post-menarcheal adolescents, dosing is same as adults: 1 tablet orally once daily for 28 days.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women. No specific dosing adjustments for elderly patients as the drug is not used in this population for contraception.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. The risk increases with age and heavy smoking (≥15 cigarettes per day) and is significant in women over 35 years old. Women over 35 who smoke should not use combined hormonal contraceptives.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache/migraine,Irregular bleeding,Ocular changes (retinal thrombosis),Depression,Hereditary angioedema,Pregnancy (discontinue if pregnancy occurs)
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Known or suspected pregnancy,Current or history of venous thrombotic disease (deep vein thrombosis, pulmonary embolism),Cerebrovascular or coronary artery disease,Current or history of migraine with aura (if age ≥35),Breast cancer or other estrogen-sensitive neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Active liver disease or benign/malignant liver tumors,Hypersensitivity to any component,Smoking cigarettes and age >35 years
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol levels; avoid large amounts. Alcohol may increase risk of liver toxicity; limit intake.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: No increased risk of major birth defects based on large cohort studies. Second and third trimesters: Associated with masculinization of female fetuses (clitoral hypertrophy, labial fusion) and possible altered pubertal development. Risk of pseudohermaphroditism is dose-dependent.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Norethindrone and ethinyl estradiol are excreted in breast milk. Estrogen components may reduce milk production. M/P ratio for norethindrone is approximately 0.7; ethinyl estradiol is <1. Use is generally not recommended during lactation.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Contraindicated in pregnancy; no dose adjustments recommended. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
NORTREL 0.5/35-28 is a monophasic combined oral contraceptive containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol. Administer daily at the same time. Breakthrough bleeding is common in the first 3-6 months. Monitor blood pressure at baseline and annually. Consider VTE risk in smokers over 35. Missed pill protocol: if one pill is missed, take as soon as remembered; if two or more, use backup contraception for 7 days.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time, in the order shown on the blister pack.,If you miss a pill, follow the package insert instructions and use backup contraception if needed.,Common side effects include nausea, breast tenderness, and spotting between periods.,Do not smoke while taking this medication, especially if over 35 years old.,Report symptoms of blood clots, including leg pain/swelling, chest pain, or sudden shortness of breath.,This medication does not protect against HIV or other sexually transmitted infections.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORTREL 0.5/35-28 vs ADQUEY, answered by our medical review team.
NORTREL 0.5/35-28 is a Oral Contraceptive that works by Norethindrone and ethinyl estradiol are a combination hormonal contraceptive. Norethindrone suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and enhances the contraceptive effect by inhibiting gonadotropin secretion.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORTREL 0.5/35-28 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORTREL 0.5/35-28 is: 1 tablet orally once daily for 28 days (21 active tablets containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol, followed by 7 placebo tablets).. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORTREL 0.5/35-28 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORTREL 0.5/35-28 is classified as Category C. First trimester: No increased risk of major birth defects based on large cohort studies. Second and third trimesters: Associated with masculinization of female fetuses (clitoral hy. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.